Cole F E, Blakesley H L, Graci K A, Frohlich E D, MacPhee A A
Peptides. 1981 Winter;2(4):441-4. doi: 10.1016/s0196-9781(81)80102-7.
125I-angiotensin II (125I-AII) binding was examined in the hypothalamic-thalamic-septal-midbrain (HTSM) region of HLA-Wistar rats in the presence of CNS-active agents. Angiotensin I, II, and III and saralasin competed for 125 I-AII binding, whereas structurally unrelated peptides such as arginine and lysine vasopressin, oxytocin, LHRH, TRH, bradykinin, and substance P did not. In contrast, ACTH and neurotensin exhibited a weak, dose-dependent competition for 125 I-AII binding. The relative potencies of AII, AI, neurotensin and ACTH were 100:1:0.1:0.05, respectively. Neurotensin and ACTH competition was not additive with AII suggesting interaction at shared binding sites. Most importantly, a wide variety of other CNS active agents such as methyldopa, naloxone, catecholamines, clondidine, and reserpine, failed to inhibit 125 I-AII binding, thus further defining the specificity of the CNS AII receptor.
在中枢神经系统活性药物存在的情况下,检测了HLA-威斯塔大鼠下丘脑-丘脑-隔区-中脑(HTSM)区域的125I-血管紧张素II(125I-AII)结合情况。血管紧张素I、II和III以及沙拉新竞争125I-AII结合,而结构不相关的肽如精氨酸和赖氨酸加压素、催产素、促黄体生成素释放激素、促甲状腺激素释放激素、缓激肽和P物质则不竞争。相反,促肾上腺皮质激素和神经降压素对125I-AII结合表现出微弱的剂量依赖性竞争。AII、AI、神经降压素和促肾上腺皮质激素的相对效力分别为100:1:0.1:0.05。神经降压素和促肾上腺皮质激素的竞争与AII不具有加和性,提示在共同结合位点存在相互作用。最重要的是,多种其他中枢神经系统活性药物如甲基多巴、纳洛酮、儿茶酚胺、可乐定和利血平未能抑制125I-AII结合,从而进一步明确了中枢神经系统AII受体的特异性。